NOVEMBER SALE - 20% OFF Everything!Shop Now
GLP-RT Peptide
99.72% HPLC purityLot-tested · COA below

GLP-RT Peptide

$71.00each · 10mg / Vial

4.8· 4 reviewsout of 5In stock

GLP-RT research vials, supplied for laboratory use only. Independent lab purity results on file for every lot, 99.72% to 99.805%, with the full COA published.

Size

Regular price $89.00Sale price $71.00You save $18.00 (20%)
1

Bundle & Save

Need more?

Select and SubscribeSave 20%
Order within 3m 03s to ship Mon, Nov 23Cutoff 5:00 PM PST · ships next business day
U.S. delivery availableFree shipping on orders over $150.00
Reship policyWrong item sent? We reship it free. Transit issues reviewed case by case.

Secure checkout · Visa · Mastercard · American Express · Discover · PayPal · Venmo · Apple Pay

Test results · tested sample

99.72%

Reported purity · Tested by Bioviridian

Tested
Sep 25, 2026
Labeled
10mg / Vial
Lab
Bioviridian
View certificate (PDF) →

Product details

GLP-RT, in brief. GLP-RT is a synthetic 39-residue peptide that acts on three receptors at once: the GIP receptor, the GLP-1 receptor and the glucagon receptor. Those three receptors normally answer to three separate hormones, and each drives a different part of how an animal handles fuel. GIP and GLP-1 receptor signalling raises insulin release when glucose is high and lowers food intake. Glucagon receptor signalling pushes liver and fat tissue to mobilise and burn stored fuel, which raises energy expenditure. Combining all three activities in one molecule lets a single compound pull on intake and on expenditure at the same time, which is the whole idea behind the design. In rodents fed a high-fat diet, that combination lowered body weight, serum lipids and liver enzyme markers. A C20 fatty diacid chain attached to one lysine lets the peptide bind albumin, which is the structural reason its action is long rather than brief. NextGenPeps supplies GLP-RT as 10 mg, 20 mg and 50 mg lyophilised research vials for laboratory use only.

What does GLP-RT do?

It switches on three metabolic receptors with one molecule. Two of them, the GIP and GLP-1 receptors, belong to the incretin system that links a meal to insulin release and to reduced feeding. The third, the glucagon receptor, does close to the opposite job in the liver: it releases stored fuel and raises the rate at which fuel is burned. A compound that engages all three can lower intake and raise expenditure in the same experiment, rather than acting on only one side of the balance.[1,2]

In cell and rodent models that comes down to three things:

  • Incretin signalling. GIP and GLP-1 receptor activation raises glucose-dependent insulin secretion from islet cells and lowers food intake in rodents.[1,9]

  • Glucagon signalling. Glucagon receptor activation in liver and adipose tissue raises energy expenditure and lipid turnover, which is the arm the two incretin receptors do not supply.[1]

  • Measured outcomes in animals. In diet-induced obese rodents, treatment lowered body weight, serum lipids and liver enzyme markers against vehicle controls.[1,3,4,5]

NextGenPeps supplies GLP-RT for in vitro research and approved animal studies only. It is not sold as a drug, supplement or diagnostic.

How does GLP-RT work?

All three receptors are class B G-protein-coupled receptors, and all three run the same core cascade. The peptide binds the receptor, the receptor couples to the Gs protein, the cell raises cyclic AMP, and protein kinase A carries the signal onward. What differs is where each receptor sits. GLP-1 and GIP receptors sit on islet cells and on neurons in feeding circuits; glucagon receptors sit mostly on hepatocytes. One shared second messenger, three different tissues, three different readouts.[1,9]

Diagram showing GLP-RT binding the GIP, GLP-1 and glucagon receptors, each signalling through Gs, cyclic AMP and protein kinase A, leading to insulin release from islet cells, lower food intake in rodent models, and higher energy use and lipid turnover in liver and adipose tissue.

Figure 1. How GLP-RT signals at three receptors.

GLP-RT engages the GIP, GLP-1 and glucagon receptors, each coupling through Gs, cyclic AMP and protein kinase A to a different tissue readout. Receptor potencies are from Coskun et al. 2022 as quoted in Katsi et al. 2025. Schematic, not to scale.[1,2]

The three potencies are not equal, and the spread matters for experimental design. At cloned human receptors the half-maximal effective concentration was 0.0643 nM at the GIP receptor, 0.775 nM at the GLP-1 receptor and 5.79 nM at the glucagon receptor, a range of about 90-fold from the most to the least potent.[1,2] Binding affinities follow the same order. Because the glucagon receptor is the least potent of the three, the glucagon arm of the pharmacology only comes fully into play at higher concentrations, which is worth holding in mind when comparing results across assay systems.

Horizontal bar chart on a log scale of GLP-RT half-maximal effective concentrations: GIP receptor 0.0643 nM, GLP-1 receptor 0.775 nM, glucagon receptor 5.79 nM.

Figure 2. GLP-RT receptor potency.

Half-maximal effective concentrations at the cloned GIP, GLP-1 and glucagon receptors, on a log scale. A shorter bar means greater potency. In vitro values only, not interchangeable with other assay systems.[1,2]

What did GLP-RT do in animal studies?

Rodents on a high-fat diet lost weight, and their blood lipids and liver enzymes moved a long way toward the values of lean controls. This is the part of the record with the most concrete numbers, so it is worth taking in detail.

In male Sprague-Dawley rats made obese on a high-fat, high-sucrose diet for eight weeks, four weeks of daily subcutaneous GLP-RT at 25 nmol/kg (n=7 per group) changed serum lipids against the vehicle group: total cholesterol fell from 232.3 to 105.9 mg/dL, triglycerides from 112.1 to 30.4 mg/dL, LDL from 171.6 to 51.3 mg/dL, and HDL rose from 38.3 to 65.8 mg/dL, all at p < 0.0001. Liver enzymes moved in the same direction, with AST at 52.43 U/L against 97.14 U/L in the vehicle group and alkaline phosphatase at 58.29 U/L against 111.71 U/L. Hepatic markers of oxidative stress and inflammation also fell and hepatic glutathione rose.[3]

Grouped bar chart of serum lipids in diet-induced obese rats, vehicle control against GLP-RT at 25 nmol/kg: total cholesterol 232.3 against 105.9 mg/dL, triglycerides 112.1 against 30.4 mg/dL, LDL 171.6 against 51.3 mg/dL, and HDL 38.3 against 65.8 mg/dL.

Figure 3. What GLP-RT did in diet-induced obese rats.

Serum lipids after four weeks of daily GLP-RT at 25 nmol/kg against vehicle control, n=7 per group, in male Sprague-Dawley rats on a high-fat, high-sucrose diet. Values are taken from the published tables of Al-Shibil and Kadhim 2026.[3]

A companion report from the same rat model records lower body weight, lower blood glucose and lower serum insulin in the treated group against untreated obese rats, with glucose at 85.71 mg/dL after four weeks against 107.00 mg/dL before treatment in the same animals.[4]

Head-to-head work in db/db mice puts the triple agonist against narrower agonists. Animals received 10 nmol/kg daily by subcutaneous injection for 10 weeks (n=6 per group), compared with a GLP-1-only agonist and a GLP-1 plus GIP dual agonist. At 10 weeks the triple agonist group had the lowest body weight and the lowest food intake of the three, followed by the dual agonist and then the GLP-1-only agonist. Glycated haemoglobin, ALT, AST, total cholesterol, triglycerides and LDL all improved most in the triple agonist group, as did renal inflammatory and fibrotic markers.[5]

Two further rodent findings round out the picture. In obese mice, GLP-RT slowed gastric emptying in a dose-dependent way from 0.3 nmol/kg upward, and over 10 days of daily dosing at 10 nmol/kg it produced a larger fall in body weight and in cumulative food intake than a GLP-1-only comparator or a long-acting glucagon receptor agonist, given alone or together (n=5 per group); the gastric emptying delay itself was attenuated by day 10.[6] In a 31-day diet-induced steatohepatitis mouse model, dosing over the final two weeks lowered body weight, liver enzymes, hepatic lipids and inflammatory markers against vehicle in female mice.[7]

For class context, a different GLP-1, GIP and glucagon triagonist peptide (not GLP-RT) given at 5 or 10 nmol/kg daily for 27 days to diet-induced obese mice produced body weight falls of 18.55 ± 1.28% and 29.64 ± 1.29% in females and 25.33 ± 1.67% and 42.82 ± 1.56% in males, with resolution of steatohepatitis in most animals at the higher dose.[8] Those figures belong to that molecule, not to GLP-RT, and are included only to show the range reported for triple agonism in rodents.

GLP-RT vs GLP-S and GLP-TZ: receptor targets

The three differ in how many of the three receptors they engage. Nothing below compares how well they work; it is a map of targets and class, not of effect.

  • GLP-S. GLP-1 receptor only. Class: single incretin receptor agonist.

  • GLP-TZ. GLP-1 receptor plus GIP receptor. Class: dual incretin receptor agonist.

  • GLP-RT. GLP-1 receptor plus GIP receptor plus glucagon receptor. Class: triple receptor agonist, two incretin receptors and one non-incretin receptor.[1,2]

The practical consequence for a study design is which arms of the pharmacology are present. Only the triple agonist carries a glucagon receptor arm, so only it can be used to ask what that arm adds on top of incretin signalling in the same animal.

What is GLP-RT made of?

It is a single chain of 39 amino acids with a C-terminal amide, built on an incretin-family backbone and then modified in three ways to make it stable and long acting.[1]

  • Non-natural residues. Two aminoisobutyric acid (Aib) substitutions at positions 2 and 20 and an alpha-methyl-leucine at position 13 stiffen the helix and block the proteases that clear native incretins quickly.

  • Fatty acid chain. A C20 fatty diacid is attached to the lysine at position 17 through a gamma-glutamate and an AEEA spacer. The chain binds albumin, which is what converts a short-lived peptide into a long-acting one.

  • Composition. Molecular formula C221H342N46O68, molecular weight 4731.33.

Sequence (one-letter, with modifications): Y-Aib-QGTFTSDYSI-(alpha-Me-Leu)-LDK-K(C20 diacid-gammaGlu-AEEA)-AQ-Aib-AFIEYLLEG-GPSSGAPPPS-NH2.

GLP-RT at a glance

  • Compound: GLP-RT

  • Class: Synthetic lipidated peptide; agonist at the GIP, GLP-1 and glucagon receptors

  • Sequence: 39 residues, C-terminal amide, two Aib substitutions, one alpha-methyl-leucine, C20 fatty diacid on Lys17 via gamma-glutamate and AEEA

  • Molecular formula: C221H342N46O68

  • Molecular weight: 4731.33

  • Receptor potency (EC50): GIP receptor 0.0643 nM, GLP-1 receptor 0.775 nM, glucagon receptor 5.79 nM[1,2]

  • Strength per vial: 10 mg, 20 mg or 50 mg

  • Identity and purity: 99.72% on the 10 mg lot and 99.77% on the 20 mg lot (independent labs, September 25, 2026); 99.805% on the 50 mg lot (March 18, 2026). Certificates for every lot are published in the COA library

  • Endotoxin: Under 0.05 EU/ml on the 10 mg and 20 mg lots, tested per USP <85>. The 50 mg lot was not endotoxin tested

  • Appearance: White lyophilised powder, sealed vial

  • Reconstitution: Sterile or bacteriostatic water

  • Regulatory status: Research use only. Not an approved drug, supplement or diagnostic

Is GLP-RT FDA approved?

No. GLP-RT is a research material, not an approved drug. It is supplied for in vitro work and approved animal studies only, and it is not sold as a drug, supplement or diagnostic. Nothing on this page should be read as a statement about the regulatory status of any other compound.

What is GLP-RT used to study?

The reason to reach for a triple agonist rather than a narrower one is almost always to isolate what the glucagon receptor arm contributes. Each use below leans on a different part of the molecule.

  • Receptor pharmacology. Cells expressing a single cloned receptor are used to measure potency, selectivity and cyclic AMP output at each of the three targets.[1]

  • Diet-induced obesity in rodents. Body weight, food intake, energy expenditure and body composition in high-fat-fed mice and rats.[1,3,6]

  • Hepatic lipid handling and steatohepatitis models. Liver enzymes, hepatic lipid content and inflammatory and fibrotic markers in diet-induced models.[3,7]

  • Comparative incretin pharmacology. Head-to-head rodent studies against GLP-1-only and GLP-1 plus GIP agonists, used to separate what each added receptor arm does.[5]

  • Gastrointestinal transit. Gastric emptying in mice, including how the effect changes with repeated dosing.[6]

Buying GLP-RT for research: what each vial includes

Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library. The 10 mg and 20 mg lots were analysed on September 25, 2026: identity by LC-MS/MS, purity by RP-HPLC at 214 nm, content by HPLC quantitation, and endotoxin per USP <85>. The 50 mg lot was analysed on March 18, 2026 by UHPLC with mass spectrometry, and that lot carries no endotoxin result.

  • Verified identity and purity. 99.72% (10 mg), 99.77% (20 mg) and 99.805% (50 mg); every certificate is published in the COA library.

  • Endotoxin, where tested. Under 0.05 EU/ml on the 10 mg and 20 mg lots. No endotoxin test was run on the 50 mg lot, so no endotoxin claim is made for it.

  • US-based fulfilment. Orders ship within 24 hours from the United States, with free US shipping on orders over $150.

  • Research use only. GLP-RT is sold strictly for in vitro and approved animal research. It is not for human or veterinary use.

GLP-RT handling, storage and analytical notes

Format. Supplied as lyophilised powder in a sealed vial and reconstituted with sterile or bacteriostatic water. No dosing instructions are supplied, and none should be inferred from the animal studies above.

Storage. Keep the sealed vial cold, at 2 to 8 degrees C, or at minus 20 degrees C for longer holding, protected from light. After reconstitution hold the solution at 2 to 8 degrees C and avoid repeated freeze-thaw cycles. The lot certificates record a storage temperature of 2 to 8 degrees C.

Counterion. Lipidated peptides purified by RP-HPLC commonly carry a residual trifluoroacetate counterion, which adds to total weighed mass and can shift apparent solubility. Quantitative work should calibrate against net peptide content rather than gross vial weight.

Solubility. The C20 diacid chain makes the molecule markedly more lipophilic than a plain peptide of similar length, and it binds albumin, so assay buffers containing serum or albumin will not report the same free concentration as protein-free buffers.

Cross-assay comparison. The EC50 values above come from cloned single-receptor systems. Potency ratios measured in primary cells or in tissue will not match them exactly, so comparisons should be made within one assay format.[1]

What is not established about GLP-RT

  • The size of the glucagon contribution. The glucagon receptor is the least potent of the three targets, and how much of the rodent outcome it accounts for at any given exposure has not been resolved.[1]

  • Transfer between species and models. The numbers above come from rats and mice on specific diets, at specific doses, over weeks. They do not transfer to other species, other models or other exposures.[3,5,6,7]

  • Long-term and tissue-level effects. Rodent studies to date run for weeks, not for the lifespan of the animal, so durability of the changes and any late tissue effects are unknown.[3,5]

  • Research-grade material. Research-grade peptide is not manufactured to the potency, sterility or stability standards of a pharmaceutical product, and no stability dataset is supplied with it.


Research Use Only. The statements made within this website have not been evaluated by the US Food and Drug Administration. These materials are not intended to diagnose, treat, cure or prevent any disease and are not intended for human or veterinary use. Studies described on this page are reported for scientific context and are not guidance of any kind.

Published research

Diet-induced obesity and hepatic lipid handling in rodents

In male Sprague-Dawley rats on a high-fat, high-sucrose diet, 25 nmol/kg daily for four weeks lowered total cholesterol from 232.3 to 105.9 mg/dL, triglycerides from 112.1 to 30.4 mg/dL and LDL from 171.6 to 51.3 mg/dL against vehicle, raised HDL from 38.3 to 65.8 mg/dL, and lowered AST and alkaline phosphatase. Hepatic oxidative stress and inflammatory markers fell.

Body weight, lipid profile, liver function, oxidative stress and inflammation in experimental obesity in male rats (Eur J Clin Exp Med 2026, reference 4) →

Compound information

Molecular Class
Synthetic lipidated peptide; agonist at the GIP, GLP-1 and glucagon receptors
Sequence
Y-Aib-QGTFTSDYSI-(alpha-Me-Leu)-LDK-K(C20 diacid-gammaGlu-AEEA)-AQ-Aib-AFIEYLLEG-GPSSGAPPPS-NH2
Length
39 amino acids, C-terminal amide
Molecular Formula
C221H342N46O68
Molecular Weight
4731.33
Lipidation
C20 fatty diacid on Lys17 via a gamma-glutamate and AEEA spacer; binds albumin
Receptor potency (EC50)
GIP receptor 0.0643 nM; GLP-1 receptor 0.775 nM; glucagon receptor 5.79 nM (cloned human receptors, in vitro)
Strength
10 mg, 20 mg or 50 mg per vial
Physical Form
White lyophilised powder, sealed vial
Purity
99.72% (10 mg lot) and 99.77% (20 mg lot), independent labs, Sep 25, 2026; 99.805% (50 mg lot), Mar 18, 2026
Endotoxin
Under 0.05 EU/ml per USP <85> on the 10 mg and 20 mg lots. The 50 mg lot was not endotoxin tested
Regulatory status
Research use only. Not an approved drug, supplement or diagnostic

Storage & stability

  • Lyophilised powder in a sealed vial
  • Store cold and protected from light
  • Avoid repeated freeze-thaw cycles
  • Calibrate quantitative work against net peptide content, not gross vial weight
Lyophilised
2 to 8 degrees C, or minus 20 degrees C for longer holding, in the sealed vial
Reconstituted
2 to 8 degrees C, protected from light
Reconstitute with
Sterile or bacteriostatic water
Certificate storage temperature
2 to 8 degrees C, as recorded on the lot certificates

Cited literature

  1. 01
    LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

    Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, et al. · Cell Metabolism 2022 · PubMed · DOI

    Primary report of the molecule's design and receptor pharmacology, and of body weight and glucose outcomes in diet-induced obese mice, attributed to glucagon receptor driven energy expenditure plus GIP and GLP-1 driven lower intake. Cell Metab 2022;34(9):1234-1247.e9. The full text sits behind a paywall, so the receptor potency values cited here were read from the open-access review by Katsi et al. 2025.

  2. 02
    Retatrutide—A Game Changer in Obesity Pharmacotherapy

    Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K · Biomolecules 2025 · DOI · Free full text

    Open-access narrative review. Quotes the receptor EC50 values (GIP 0.0643 nM, GLP-1 0.775 nM, glucagon 5.79 nM) and summarises the rodent literature. A narrative review, not a systematic one, and it reports values at second hand.

  3. 03
    Effect of retatrutide on body weight, lipid profile, liver function, oxidative stress, and inflammation in experimental obesity in male rats

    Al-Shibil ZMR, Kadhim ZJ · European Journal of Clinical and Experimental Medicine 2026 · DOI · Free full text

    Male Sprague-Dawley rats on a high-fat, high-sucrose diet, 25 nmol/kg daily subcutaneously for four weeks, n=7 per group; the source of the lipid and liver enzyme values charted on this page. The paper's own abstract reports AST, ALP and body weight figures that do not match its tables, so only the tabulated values are used here.

  4. 04
    Retatrutide counteracts liver impairment in high-fat/sucrose diet induced obesity in male rats

    Al-Shibil ZMR, Kadhim ZJ · Kufa Journal of Pharmaceutical Sciences 2026 · Free full text

    Companion report from the same rat model and the same 25 nmol/kg regimen, recording lower body weight, blood glucose, serum insulin and AST. Group sizes beyond the control arm are not stated and no p-values are given.

  5. 05
    Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice

    Ma J, Hu X, Zhang W, Tao M, Wang M, Lu W · Endocrine 2024 · PubMed

    Head-to-head rodent comparison of a GLP-1-only agonist, a GLP-1 plus GIP dual agonist and the triple agonist at 10 nmol/kg daily for 10 weeks in db/db mice, n=6 per group. Small groups and a single dose level, and db/db mice are a genetic rather than a diet-induced model.

  6. 06
    The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying

    Urva S, O'Farrell L, Du Y, Loh MT, Hemmingway A, Qu H, Alsina-Fernandez J, Haupt A, Milicevic Z, Coskun T · Diabetes, Obesity and Metabolism 2023 · PubMed · DOI

    Obese mice, n=5 per group: dose-dependent delay of gastric emptying from 0.3 nmol/kg, and greater falls in body weight and food intake over 10 days at 10 nmol/kg than comparator agonists. Mouse outcomes are reported graphically, so exact values are not recoverable from the text.

  7. 07
    Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge

    Viebahn GK, Khurana A, Freund L, et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology 2025 · PubMed · DOI

    31-day diet-induced steatohepatitis mouse model with dosing over the final two weeks: lower body weight, liver enzymes, hepatic lipids and inflammatory markers against vehicle. Am J Physiol Gastrointest Liver Physiol 2025;329(6):G680-G695. The treatment effect is reported in female mice only.

  8. 08
    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice

    Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi RD, Tschop MH, Muller TD, Hofmann SM · Molecular Metabolism 2017 · PubMed · DOI · Free full text

    Diet-induced obese mice given 5 or 10 nmol/kg daily for 27 days: body weight fell 18.55 +/- 1.28% and 29.64 +/- 1.29% in females and 25.33 +/- 1.67% and 42.82 +/- 1.56% in males, with resolution of steatohepatitis at the higher dose. Important limitation: this is a different triagonist peptide, not GLP-RT, and is cited only as class context.

  9. 09
    Glucagon-like peptide 1 (GLP-1)

    Muller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. · Molecular Metabolism 2019 · PubMed · DOI

    Comprehensive open-access review of GLP-1 receptor biology, used here for background on incretin signalling. Mol Metab 2019;30:72-130. Covers GLP-1 rather than the triple agonist itself.

Frequently asked questions

How is GLP-RT packaged?

GLP-RT is supplied in the product format and quantity shown for the selected variant. Please inspect the sealed package when it arrives and contact support promptly if the package or labeling appears damaged.

How is GLP-RT shipped?

Orders are shipped within the United States via USPS. Transit times are typically 3–7 business days, depending on destination and carrier conditions. Tracking information is provided when available.

How should GLP-RT be stored?

Storage requirements are product-specific. Keep GLP-RT in its original labeled container and follow the product documentation or manufacturer instructions supplied with the order. Contact support if the applicable storage guidance is not available.

What is the refund policy for GLP-RT?

Due to the nature of research materials, NextGenPeps orders are final and are not eligible for refunds, returns, or exchanges. Review the shipping and reship policies before ordering.

Is GLP-RT intended for human use?

No. NextGenPeps materials are supplied strictly for laboratory research and development use and are not intended for human or animal consumption, clinical use, diagnostic use, cosmetic use, or dietary use.

Customer reviews

4.8out of 5 · 4 reviews

Reliable Research Materials

COA testing confirms consistency across different vial sizes. HPLC analysis Illustrates the reproducible purity at each fill volume.

Benjamin S.

Good Product

No problem reconstituting. Came out clear without clouds, color changes, or floaters

Caleb R.

Amazing pricing

A really good price, I always stock up here when it goes on sale

Natalie H.

Responsive Support

The support solved all my problems at checkout and got back to me quickly. They were able to walk me through it over the phone in real time, not some AI response.

Charlotte K.

Common research questions

What is GLP-RT?

GLP-RT is a synthetic 39-residue peptide supplied as a research material. It acts as an agonist at three receptors at once: the GIP receptor, the GLP-1 receptor and the glucagon receptor. A C20 fatty diacid chain attached to the lysine at position 17 binds albumin and is the structural reason its action is long rather than brief. It is studied in cell systems and in rodent models of diet-induced obesity and hepatic lipid accumulation, and it is not an approved drug.

How does GLP-RT work at the receptor level?

All three of its targets are class B G-protein-coupled receptors that couple through the Gs protein, raise cyclic AMP and activate protein kinase A. The difference is where the receptors sit: GLP-1 and GIP receptors on islet cells and on neurons in feeding circuits, glucagon receptors mostly on hepatocytes. At cloned human receptors the half-maximal effective concentrations were 0.0643 nM at the GIP receptor, 0.775 nM at the GLP-1 receptor and 5.79 nM at the glucagon receptor, a spread of roughly 90-fold.

What does adding the glucagon receptor change?

Incretin receptor signalling mainly lowers food intake and raises glucose-dependent insulin release. Glucagon receptor signalling in liver and adipose tissue works on the other side of the energy balance, raising energy expenditure and lipid turnover. In diet-induced obese mice the change in body weight was attributed to higher energy expenditure through the glucagon receptor combined with lower intake through the GIP and GLP-1 receptors, which is why a triple agonist is used when a study needs both arms present in the same animal.

What happened in rodent studies of GLP-RT?

In male Sprague-Dawley rats on a high-fat, high-sucrose diet, four weeks of 25 nmol/kg daily lowered total cholesterol from 232.3 to 105.9 mg/dL, triglycerides from 112.1 to 30.4 mg/dL and LDL from 171.6 to 51.3 mg/dL against vehicle, while HDL rose from 38.3 to 65.8 mg/dL. AST fell to 52.43 U/L from 97.14 U/L. In db/db mice dosed at 10 nmol/kg daily for 10 weeks, body weight and food intake were lower than with a GLP-1-only agonist or a GLP-1 plus GIP dual agonist. These are rodent findings at specific doses and do not transfer to other species or models.

How does GLP-RT differ from GLP-S and GLP-TZ?

The difference is how many receptors each engages. GLP-S targets the GLP-1 receptor only and is a single incretin receptor agonist. GLP-TZ targets the GLP-1 and GIP receptors and is a dual incretin receptor agonist. GLP-RT targets the GLP-1, GIP and glucagon receptors and is a triple receptor agonist. Only GLP-RT carries a glucagon receptor arm, so only it can be used to ask what that arm adds on top of incretin signalling. No comparison of effectiveness is offered here.

What is GLP-RT made of, and how is each lot tested?

It is a single 39-residue chain with a C-terminal amide, two aminoisobutyric acid substitutions, an alpha-methyl-leucine, and a C20 fatty diacid on the lysine at position 17 through a gamma-glutamate and AEEA spacer. The molecular formula is C221H342N46O68 and the molecular weight 4731.33. Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library: purity was 99.72% on the 10 mg lot and 99.77% on the 20 mg lot (September 25, 2026) and 99.805% on the 50 mg lot (March 18, 2026). Endotoxin was under 0.05 EU/ml on the 10 mg and 20 mg lots; the 50 mg lot was not endotoxin tested.

Frequently Researched with

GHK-Cu

✓ 99.73% purity

GHK-Cu

$74.00$59.00

GLOW

✓ 99.71% purity

GLOW

$134.00$107.00

BPC-157

✓ 99.748% purity

BPC-157

$46.00$37.00

You have an unfinished subscription checkout

Continue your saved checkout, or replace its item with . Your saved selection and existing subscriptions will stay unchanged.

Continue saved checkout
NextGenPeps

Reliable and innovative research with our top-grade research materials and novel research compounds tailored to lead the competitive research industry. Choose research quality. Choose NextGenPeps.

Customer Service: +1 (971) 300-1435

Get 10% Off Your First Order

Sign up now and receive a 10% discount code valid on your next purchase!

Nextgenpeps LLC

The statements made within this website have not been evaluated by the US Food and Drug Administration. The materials offered by this company are not intended to diagnose, treat, cure, or prevent any disease. All research materials on this site are for laboratory research and development use only, and are not intended for human use.

NextGenPeps is a chemical supplier. NextGenPeps is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. NextGenPeps is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.

Privacy PolicyTerms & ConditionsAffiliate Program

501 W Broadway Ste A, San Diego, CA 92101

© 2026 NextGenPeps. All rights reserved.

Visa
American Express
Mastercard
PayPal
Discover
Apple Pay